DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus.

Gesine van MarkSascha R TittelReinhard WelpJörg GloyerStefan SziegoleitRalf BarionPeter M JehleDieter ErathPeter BramlageStefanie Lanzinger

Published in: BMJ open diabetes research & care (2021)

BIA were used in more individually and patient-centered therapy regimens compared with HI/NPH in patients with a mean age of 80 years. Both groups were slightly overtreated with mean HbA1c <7.5%. The risk of severe hypoglycemia was low and independent of insulin type. Further analyses of elderly patients with type 2 diabetes are needed to provide evidence for best practice approaches in this age group.

Keyphrases

type diabetes
glycemic control
community dwelling
middle aged
primary care
physical activity
human health
stem cells
insulin resistance
quality improvement
mesenchymal stem cells
climate change
adipose tissue